NCT07008378View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

August 31, 2032

Study Completion Date

August 31, 2032

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

P-CD19CD20-ALLO1 Cells

P-CD19CD20-ALLO1 Cells will be administered intravenously as per the schedule specified in the protocol.

DRUG

Cyclophosphamide

Cyclophosphamide will be administered intravenously.

DRUG

Fludarabine

Fludarabine will be administered intravenously.

Trial Locations (1)

63110-1010

RECRUITING

Washington University School of Medicine, St Louis

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
collaborator

Poseida Therapeutics, Inc., a member of the Roche Group

UNKNOWN

lead

Genentech, Inc.

INDUSTRY